

ONE YEAR OF COVID-19 RESEARCH

NON COVID STUDIES PAUSED

Studies paused to prioritise and accelerate the delivery of COVID-19 research.

R&D staff redeployed to support Trust response and 7-day research service launched.

COVID Research Committee set-up to review and coordinate activity.

Patient & Public Research Advisory Group review first COVID Studies.

Arden Tissue Bank commences the collection of COVID samples.

RESTART OF NON-COVID TRIALS

R&D commences the re-opening of paused non-COVID research alongside COVID trial delivery.

The Trust recruits its 100th patient into the RECOVERY trial.

WORKING DIFFERENTLY

Non-clinical R&D team continue to undertake data entry for national priority trials.

RECRUITMENT ACHIEVEMENTS

The Trust recruits its 200th patient recruited to the RECOVERY trial.

A Midlands Health Alliance [COVID Report](#) is released featuring UHCW COVID research.

The ACCORD-2 trial testing several different drugs to understand how they improve clinical outcomes in patients opens at the Trust and quickly exceeds its recruitment target.

COVID REHABILITATION STUDY FUNDED

Trust researchers awarded £1.1m by the NIHR HTA Programme for the REGAIN COVID rehabilitation study.

The Trust recruits the first patient into the IONIC trial.

SIREN STUDY

The SIREN study looking to understand whether prior COVID infection protects against future infection is completed, recruiting 253 staff in just 44 days.

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

NOV

DEC

JAN

FEB

RECOVERY TRIAL OPENS

The national RECOVERY trial testing potential treatments for COVID-19 opens at the Trust and recruits its first patients.

Delivery to Doorstep protocols set up enabling patients to receive medication directly to their home.

UHCW-led PatientTrackers™ rolled out to support COVID research patient management across the West Midlands.

R&D staff feature in media, including Panorama and a blog in the [BMJ](#).

COVID CANINE STUDY OPENS

A study investigating whether dogs can be trained to identify odours associated with COVID-19 opens.

IONIC TRIAL OPENS

UHCW researchers, supported by the Trust's Trial Management Unit, open the IONIC trial exploring the potential benefits of a novel drug with an anti-viral for the treatment of COVID. The trial was set-up and open to recruitment in just 10 weeks.

The RECOVERY trial finds that dexamethasone reduces mortality in those requiring oxygen or ventilation.

RE-MAP CAP COMMENCES

Recruitment of the first patients into the convalescent plasma trial as part of the REMAP-CAP platform

UHCW DELIVERS FIRST NON-TRIAL VACCINE

Landmark moment as the first COVID patient receives a vaccination outside of clinical trials at the Trust.

The REGAIN and COASPIRE trials open.

Trust R&D teams recognised in West Midland CRNWM Awards successes, including CRN Digital Innovation Award (winner) for the PatientTracker™.

RESTART

70% of non-COVID trials have been restarted.

The RECOVERY trial shows tocilizumab reduces deaths in patients hospitalised with COVID-19.

UK-REACH Study investigating Ethnicity and COVID-19 outcomes in Healthcare workers open.

Data captured for 2101 COVID patients as part of the ISARIC trial.

We would like to thank everyone who has contributed to these extraordinary achievements in the last year, and particularly to the patients and staff who have taken part in clinical trials.

3100 patients recruited into NIHR Portfolio trials

2862


Recruited into UPH* trials



238

Recruited into non-UPH trials

1711 Recruited to non-COVID trials



NIHR portfolio COVID studies opened

■ Non-commercial

Plus 58 local research studies, service evaluations or data/sample collection studies

COVID Research in numbers

31k samples stored and available to researchers



51 grants submitted
£1.4m income secured



64 peer reviewed publications

